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A B S T R A C T
Background: Ageing is a highly complex process marked by a temporal cascade of events, which promote al-
terations in the normal functioning of an individual organism. The triggers of normal brain ageing are not well
understood, even less so the factors which initiate and steer the neuronal degeneration, which underpin dis-
orders such as dementia. A wealth of data on how nutrients and diets may support cognitive function and
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T
Neuro-inﬂammation
Plant-food bioactives
preserve brain health are available, yet the molecular mechanisms underlying their biological action in both
normal ageing, age-related cognitive decline, and in the development of neurodegenerative disorders have not
been clearly elucidated.
Objectives: This review aims to summarise the current state of knowledge of vulnerabilities that predispose
towards dysfunctional brain ageing, highlight potential protective mechanisms, and discuss dietary interventions
that may be used as therapies. A special focus of this paper is on the impact of nutrition on neuroprotection and
the underlying molecular mechanisms, and this focus reﬂects the discussions held during the 2nd workshop
‘Nutrition for the Ageing Brain: Functional Aspects and Mechanisms’ in Copenhagen in June 2016. The present
review is the most recent in a series produced by the Nutrition and Mental Performance Task Force under the
auspice of the International Life Sciences Institute Europe (ILSI Europe).
Conclusion: Coupling studies of cognitive ageing with studies investigating the eﬀect of nutrition and dietary
interventions as strategies targeting speciﬁc mechanisms, such as neurogenesis, protein clearance, inﬂammation,
and non-coding and microRNAs is of high value. Future research on the impact of nutrition on cognitive ageing
will need to adopt a longitudinal approach and multimodal nutritional interventions will likely need to be
imposed in early-life to observe signiﬁcant impact in older age.
1. Introduction
By 2030, the number of people aged 60 years or over is predicted to
grow by 56% from 901 million to 1.4 billion (United Nations
Department of Economic and Social Aﬀairs, 2015). By 2050, the like-
lihood of developing neurodegenerative diseases, such as Alzheimer’s
or vascular dementia (VD) will increase by 45% (Alzheimer’s, 2015). As
a result, all nations will need to divert an increasing proportion of their
healthcare funding to treat and manage dementia and other age-related
cognitive diseases. It is predicted that by 2050, increases in the ageing
population will present signiﬁcant economic and social challenges and
the burden for healthcare systems and on society will become en-
ormous. The current cost of dementia alone is €725 billion worldwide
and is expected to reach €1,7 trillion by 2030 (Alzheimer’s Disease
International and International, 2015). The costs of dementia care are
very substantial, and a large proportion of the costs also fall to unpaid
carers. The value concerning loss of quality of life of people with de-
mentia needs to be considered in addition to the costs of care.
To address this major global challenge, research funding and eﬀort
has increasingly focused on the mechanisms associated with brain
ageing and cognitive decline. The number of publications studying
cognitive decline is currently around 16,000, and this growing body of
research is increasing rapidly, as scientists and governments seek to
identify solutions to the coming challenges.
There is overwhelming evidence that major aspects of cognitive
function decline from early adulthood onwards, even in cognitively
healthy individuals (Salthouse, 2010; Salthouse, 2012a,b). This decline
starts during the third decade of life, aﬀects many dimensions of cog-
nitive function, and occurs in all individuals (Salthouse, 2010). There
are two major stages to healthy brain ageing, ﬁrst maturation and de-
velopment to adulthood, and second the maintenance of function from
adulthood to old age (Salthouse, 2010; Salthouse, 2012a,b). Cognitive
function tends to improve over the ﬁrst 18 years of life, peak during the
next few years, and then deteriorate steadily thereafter (Salthouse,
2010; Salthouse, 2012a,b). In the absence of adequate nutrition or in
the presence of a variety of disease states, cognitive function in ‘healthy’
individuals will be detrimentally perturbed during their lifetime. Most
people will encounter disease at some stage of their life, with the ma-
jority of diseases associated with some form of negative consequences
for cognitive function (Wesnes, 2006). However, evidence is accumu-
lating that cognitive decline during normal ageing can be attenuated by
a wide variety of factors, such as improved nutrition, appropriate
dietary supplementation, increased physical exercise, and the perfor-
mance of mental exercises (Barberger-Gateau, 2014; Ferreira et al.,
2015; Gupta, 2016; Makin, 2016; McGilvray, 2016).
In 2016, the ILSI Europe’s Nutrition and Mental Performance Task
Force organised the 2nd workshop in a series on ‘Nutrition for the
Ageing Brain’. To capture the value of this workshop, the aim of this
paper is to review the vulnerabilities associated with poor cognitive
ageing, highlight potential protective mechanisms and how dietary
interventions can be a strategy to target some of these mechanisms, and
address future research priorities to ameliorate the eﬀects of brain
ageing. This review focuses on molecular mechanisms including the
novel angles covered by the workshop.
2. Vulnerabilities associated with poor cognitive ageing
2.1. Early-life stress
Research with humans and animals has demonstrated that the brain
is sensitive to stress and is especially vulnerable during early childhood
and old age (Benton, 2010; Jane Costello et al., 2007; Maselko et al.,
2011; Nelson and Trainor, 2007; Walker et al., 2000). Exposure to
early-life stress (ES) is associated with lasting changes in the structure
of the adult brain and accelerated cognitive decline. A possible role for
epigenetic mechanisms, involving DNA methylation changes has been
suggested, although the underlying molecular mechanisms remain lar-
gely unknown (Bale, 2015; Blouin et al., 2016; Sheerin et al., 2017;
Weaver et al., 2004; Yao et al., 2016). Animal studies impose ES using
interventions, such as limited access to nest and bedding material
(Molet et al., 2014; Naninck et al., 2015). Such interventions are
thought to mimic important aspects of human chronic ES and are
considered valuable tools to investigate the mechanisms linking ac-
celerated cognitive decline with ES. So far, the lasting eﬀects of ES on
cognition have been attributed mostly to alterations in maternal care
and neuroendocrine factors (Naninck et al., 2015; Teicher et al., 2012),
while the role of early nutrition has been largely ignored. However,
both ES and early-life malnutrition often occur simultaneously, and it
may be important to investigate the separate and interactive con-
sequences for cognition (Naninck et al., 2013). If early-life nutrition is
involved in mediating ES eﬀects on brain structure and function, it is
likely that the lasting eﬀects of ES result from the synergistic action of:
1) the quality and quantity of early nutrition 2) stress hormones and 3)
sensory stimuli from the mother (Lucassen et al., 2013). Therefore, it is
important to study if (and how) ES alters the nutritional/metabolic
environment in both the mother and her oﬀspring. Such an integrated
approach provides new opportunities for devising nutritional inter-
vention strategies that prevent enduring eﬀects of ES on mental health.
As ES exposure often cannot be prevented, a deeper understanding of
all elements involved in early programming of the brain by ES is re-
quired to develop novel treatment strategies to protect vulnerable in-
dividuals from the lasting eﬀects of ES. The eﬀects of various elements
of the early-life environment (e.g. maternal care, neuro-endocrine fac-
tors, nutrient availability, and metabolic hormones) are often con-
sidered in isolation, despite the intense crosstalk between stress and
metabolic programming. However, emerging evidence demonstrates
that enriching the diet early in life with essential micronutrients pre-
vents some of the negative consequences of ES, opening new
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perspectives for nutritional interventions (Naninck et al., 2017).
2.2. Gut microbiome
Early-life stress in animals results in changes in the microbiome in
adulthood (O’Mahony et al., 2009). Speciﬁc changes in the stress re-
sponse are linked to changes in the functioning of the gut-brain axis
(Dinan and Cryan, 2013). Furthermore, there is evidence of co-mor-
bidity between gastrointestinal conditions and stress-related psychiatric
symptoms (Kennedy et al., 2012).
The gut microbiota inﬂuences development and homeostasis in
adulthood (Claesson et al., 2012). Unlike healthy adults, the composi-
tion of the intestinal microbiota of those aged above 65 shows more
inter-individual variation (Biagi et al., 2010; Claesson et al., 2011). The
microbiota proﬁles of ageing individuals have been associated with the
degree of retention of a core microbiome, long-term residential care,
and age and habitual diet (O’Toole and Jeﬀery, 2015). The composition
of faecal microbiota in the elderly has also been found to correlate with
frailty and co-morbidity (Claesson et al., 2012). Speciﬁcally, the gut
microbiota has been shown to modulate the gut-brain axis, through
which it exerts an inﬂuence on both cognitive function and plasticity
during ageing (Leung et al., 2015).
Diﬀerences in the microbiota of young and adult mice fed a control
diet have been found to inﬂuence social behaviour (Palma et al., 2014).
In a series of behavioural experiments, young mice showed signiﬁcantly
elevated exploratory behaviour of a displaced object relative to aged
mice, and aged mice explored the open arms of a maze signiﬁcantly less
than young mice. Furthermore, young mice demonstrated signiﬁcantly
greater exploration of a novel mouse compared to aged mice in a social
recognition experiment (Desbonnet et al., 2014; Heijtz et al., 2011).
Ageing has also been associated with an increase in gut permeability.
Oral administration of ﬂuorophores-conjugated macromolecules (i.e.
ﬂuorescein isothiocyanate-dextran) in young and aged mice has shown
that aged mice have signiﬁcantly greater gut permeability, especially
following restraint stress. Moreover, the presence of proinﬂammatory
cytokines is signiﬁcantly greater in the plasma of aged mice relative to
young mice, thus showing an increased pro-inﬂammatory proﬁle in
ageing (Scott et al., 2017). Work with invertebrates has highlighted the
role of the microbiota in directly and indirectly impacting the host
genome to promote longevity. For example, worms consuming met-
formin have an increased lifespan in an AMPK-dependent manner. This
relationship is indirectly mediated by the impact of metformin on
bacterial folate metabolism (Heintz and Mair, 2014).
Germ-free animals have been used to elucidate the relationship
between gut microbiota and pathological ageing. A germ-free mouse
model of Alzheimer’s disease (AD) was found to show a reduced
number of β-amyloid plaques relative to control AD mice with intestinal
microbiota. However, the presence of plaques in the germ-free mice
increased dramatically following the introduction of microbiota har-
vested from the control mice (Harach et al., 2015). Germ-free mice
models are valuable in illustrating the importance of gut microbiota in
the gut-brain relationship. Research has shown that gut microbiota is
required for normal stress-hormone signalling, neural function, in-
cluding increased hippocampal neurogenesis, increased blood-brain
barrier permeability, regulating immune function, and anxiety-like and
sociability behaviours (Luczynski et al., 2016). Further, postnatal mi-
crobial colonisation has been implicated in brain plasticity and the
Hypothalamic Pituitary-Adrenal (HPA) stress reaction of germ-free and
speciﬁc pathogen-free (SPF) mice. Following 1 h of restraint stress,
germ-free mice had markedly higher plasma adrenocorticotropic hor-
mone (ACTH) and corticosterone levels relative to SPF mice (Sudo
et al., 2004). This HPA response in germ-free mice was partially cor-
rected three weeks following reconstitution of SPF faeces at 9 weeks of
age but not at 17 weeks, indicating that microbial colonisation at an
early stage of development is needed for the HPA system to become
fully susceptible to inhibitory neural modulation. Germ-free mice also
had signiﬁcantly lower levels of brain-derived neurotrophic factor
(BDNF) in the cortex and hippocampus to that of SPF mice (Sudo et al.,
2004). Similarly, microbial colonisation has been suggested to initiate
signalling mechanisms that inﬂuence neural circuits, which modulate
motor control and anxiety-like behaviours. Speciﬁcally, germ-free mice
showed greater motor activity and reduced anxiety when compared to
SPF mice with a normal gut microbiota (Heijtz et al., 2011). Moreover,
as well as displaying reduced anxiety-like behaviour, germ-free mice
have also shown increased explorative behaviour in comparison to SPF
mice (Neufeld et al., 2011). Interestingly, the microbiome has been
found to inﬂuence neural circuits in a gender-dependent manner. In
male germ-free animals, a signiﬁcant increase in hippocampal serotonin
levels, 5-hydroxyindoleacetic acid, and plasma concentrations of tryp-
tophan were identiﬁed relative to conventionally colonised control
animals. The elevated serotonin and 5-hydroxyindoleacetic acid con-
centrations were not inﬂuenced by colonisation post-weaning, regard-
less of tryptophan levels returning to baseline values. As such, the lack
of a normal gut microbiome has long-term consequences for central
nervous system neurotransmission, which cannot be restored following
the introduction of a normal gut microbiome in later life (Clarke et al.,
2013). Conversely, there was greater down-regulation of genes related
to the immune system (Stilling et al., 2015), which supports the sug-
gestion that germ-free mice have an under-developed immune system
(Cebra, 1999). Amygdala transcriptome alterations failed to be com-
pletely restored following colonisation with conventional microbiota
post-weaning, thus lending further support towards hypotheses invol-
ving the existence of critical stages of neuro-development (Stilling
et al., 2015). Likewise, both germ-free mice and those colonised post-
weaning have been found to have 190 and 15 genes diﬀerentially ex-
pressed in the prefrontal cortex relative to conventionally colonised
mice, respectively; with signiﬁcant overlap suggesting the absence of
microbiota during early development has irreversible consequences for
cellular functions. In particular, 19% and 27% of genes found to be up-
regulated in both mice types were associated with myelin components
or neuronal activity, respectively.
2.3. Non-communicable diseases, such as obesity, type 2 diabetes and
glucose regulation
In contrast to some infectious diseases, non-communicable diseases,
such as neurodegenerative disease, cancer, obesity, and cardiometa-
bolic disorders do not typically develop rapidly, but rather progress to a
pathological state over many years. Obesity is associated with co-
morbidities, such as chronic inﬂammation, impaired glucose tolerance,
insulin resistance, and type 2 diabetes mellitus (T2DM), and rates of
obesity are increasing. Midlife obesity is a signiﬁcant risk factor for
later life dementia (Sellbom and Gunstad, 2012), and has been found to
be associated with cognitive impairment across a range of cognitive
domains in a recent systematic review (Prickett et al., 2015). However,
in older adults, current obesity levels have been inversely associated
with dementia (Fitzpatrick et al., 2009). This could represent an
“obesity paradox” in which late life weight loss may precede dementia
(Hughes et al., 2009) and occur before a presentation of cognitive im-
pairment. A recent retrospective cohort study of almost 2 million in-
dividuals aged over 40 years in the UK reported that being underweight
in middle age and old age carries an increased risk of dementia
(Qizilbash et al., 2015). However, this is controversial and in contrast to
the evidence of an association between obesity and dementia. This
ﬁnding may therefore reﬂect the possible tendency to underdiagnose
dementia by general practitioners at the time the data was collected,
and over or under adjustment for a number of factors, such as com-
peting risk of mortality, selection bias, and bias in the diagnosis of
dementia in those with lower BMI/age (Harrison and Shenkin, 2015).
Obesity may impact cognitive function prior to any dementia-re-
lated cognitive decline, leading to the suggestion that interventions
aimed at promoting weight loss may attenuate late-life cognitive
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decline. Midlife obesity is most consistently associated with impaired
executive function in older adults, but impairments in language, motor,
and memory performance have also been documented (Gunstad et al.,
2010). A number of mechanisms have been proposed to account for the
association between obesity and impairment of cognitive function.
These include inﬂammation, impaired cerebral metabolism or blood
ﬂow, elevated leptin, and neuronal degradation. Inﬂammatory markers
such as C-reactive protein (CRP) are found in the obese, where greater
brain atrophy, lower grey matter and total brain volume, and increased
white matter hyperintensities have also been observed (Prickett et al.,
2015). Other mechanisms suggested to account for obesity-related im-
pairment of cognitive function relate to the co-morbidities, which are
common in obese adults and apparent usually from midlife, for example
hypertension, dyslipidemia, impaired glucose tolerance, insulin re-
sistance, and T2DM.
The association between diabetes and cognitive impairment was
recognised almost a century ago (Miles and Root, 1922). Numerous
studies have compared cognitive functioning in diabetic patients with
non-diabetic controls (Brands et al., 2005). The majority of these stu-
dies detail cognitive impairments, such as decreased performance on
attention and memory tasks (Awad et al., 2004; Brands et al., 2004;
Lamport et al., 2013; Tun et al., 1990; van den Berg et al., 2009).
Performance of complex cognitive tasks appears to be more impaired as
a result of diabetes, whereas performance of less demanding tasks
seems to be comparable to controls (Tun et al., 1990). This pattern
parallels the cognitive changes of normal ageing, where age diﬀerences
are insigniﬁcant on less demanding immediate memory tasks, but more
pronounced on secondary or long-term memory tasks (Perlmuter et al.,
1984).
Impaired glucose tolerance (IGT) often occurs prior to the devel-
opment of diabetes and may contribute to cognitive impairments
(Lamport et al., 2009). Recent studies have shown that the performance
of ostensibly healthy middle-aged women with IGT was impaired in
cognitive tasks which predominantly engage the hippocampus
(Lamport et al., 2014). Interventions that improve glucose tolerance
have also been shown to improve cognitive function (Yamamoto et al.,
2009).
Since obesity and subsequent T2DM increases the risk of AD by 65%
(relative risk in T2DM is 1.46 (Cheng et al., 2012)), and around 80% of
AD patients have problems with glycaemic control, AD has been re-
ferred to as Type 3 diabetes (De La Monte and Wands, 2008). It has
been proposed that AD is a metabolic disease, mediated by impairments
in brain insulin responsiveness, glucose utilisation, and energy meta-
bolism, which leads to increased oxidative stress and inﬂammation,
which worsens insulin resistance (De La Monte and Wands, 2008).
Advanced glycation end-products (AGEs) are also elevated in both
T2DM and AD. The relative risk of VD in those with T2DM is 2.49
(Cheng et al., 2012), and its development relates to a history of hy-
pertension and disturbances in cerebral blood ﬂow. Metabolic dis-
turbances, such as insulin resistance, hyperlipidaemia, cholester-
olaemia, and impaired vascular function (e.g. increased blood pressure
and reduced cerebral blood ﬂow), which occur at sub-clinical levels in
pre-disease states, may elevate the risk of subsequent cognitive decline
and dementia (Hassing et al., 2009). Evidence from MRI studies sug-
gests that asymptomatic cerebrovascular brain injury is common, often
occurring in midlife and related to cardiovascular disease risk factors.
This implies that interventions that address cerebrovascular risk factors
during middle age may be prophylactic for cognitive ageing. One such
intervention is bariatric surgery, which has been shown to promote
rapid improvements in memory and executive function that persist for
several years postoperatively (Spitznagel et al., 2015). This post-op-
erative improvement in memory performance is not seen in individuals
with a family history of AD (Alosco et al., 2014), which suggests that
genetic vulnerability or family history may attenuate cognitive recovery
post-bariatric surgery.
2.4. Environmental factors and epigenetic modulation
Adipocytes release pro-inﬂammatory adipokines, which can pro-
mote the pathological chronic inﬂammation associated with obesity.
Epigenetic ageing can be accelerated by the cumulative addition of
chemical DNA methylation marks to the (epi)genome (Quach et al.,
2017). As such, an individual’s personal lifestyle (stress, diet, pollution,
exercise, smoking, alcohol consumption, and sleep deprivation) leaves a
trail of chemical epigenetic marks in the genome by means of cumu-
lative (stochastic) DNA methylation, which alters gene expression,
leading to a spectrum of disease/health related phenotypes. An un-
healthy lifestyle will accelerate an individual’s epigenetic age (clock)
(Mather et al., 2016; Nevalainen et al., 2017; Quach et al., 2017;
Zannas et al., 2015) as compared to their biological age, and promote
early onset of complex lifestyle diseases, such as cancer, cardiometa-
bolic diseases, and cognitive decline (Fraga et al., 2005; Wolf et al.,
2016). In contrast, a healthy lifestyle will decrease epigenetic age
(clock) relative to biological age and delay the onset of lifestyle disease
(i.e. healthy years free of disease are added). Epigenetic ageing can be
compared to the emptying of an hourglass, where lifestyle determines
the speed at which sand moves from the top to the lower compartment
(reﬂecting metabolic inﬂammatory rate). This may also explain the
rather small epigenetic impact of relatively short (6–8 weeks) diet in-
terventions in comparison to the epigenetic impact of chronic disease
promoting lifestyle conditions/exposure, which typically are persistent
over many years (smoking, stress, pollution, alcohol abuse) (Milenkovic
et al., 2014). Moreover, nutrition and exercise interventions trigger
highly variable (epigenetic) DNA methylation changes involved in
vascular inﬂammation, cardio-metabolic, cognitive health, and epige-
netic age (Quach et al., 2017). Epigenetic variation creates multiple
redundant possibilities (homeostasis) to achieve healthy ageing or to
develop premature ageing/lifestyle diseases. Inter-individual variation
in microbiome composition contributes in diﬀerent pharmacodynamics
of nutritional bioactives (Cortese et al., 2016; Paul et al., 2015; Stilling
et al., 2014). Inter-individual epigenetic variation in expression of
ADME proteins (involved in absorption, distribution, metabolism, and
excretion) further contributes to inter-individual variation through
diﬀerent pharmacodynamics of nutritional bioactives (Fisel et al., 2016;
Ingelman-Sundberg and Cascorbi, 2016). Finally, the inter-individual
epigenetic nutritional response is also co-determined by genetic single
nucleotide polymorphisms (SNPs) in genes associated with methyl (one
carbon) donor metabolism, i.e. methylenetetrahydrofolate reductase
(Anderson et al., 2012; Declerck et al., 2017; Friso et al., 2002;
Quinlivan et al., 2005; Stover, 2009).
3. Potential mechanisms underlying vulnerabilities
3.1. Neurogenesis
The hippocampus is a key brain structure associated with learning,
memory, and mood, and is one of the two structures in the adult brain
where the formation of new neurons (or neurogenesis) persists
throughout life in numerous species, including in human (Eriksson
et al., 1998; Ernst et al., 2014; Spalding et al., 2013). The functionality
of these adult-born neurons in the adult hippocampus has been linked
directly to cognition, learning, and memory (Deng et al., 2010; Eisch
and Petrik, 2012). For example, in the adult rodent, hippocampal
neurogenesis is crucial for pattern separation abilities (Clelland et al.,
2009). Hippocampal neurogenesis decreases with age in rodents, as
does pattern separation abilities in humans (and cognition in general).
Therefore, neurogenesis could be the target for interventions to prevent
or slow down cognitive ageing.
Adult hippocampal neurogenesis can be modulated by the systemic
environment (blood) in an age-dependent manner (Murphy and Thuret,
2015). Studies using heterochronic parabiosis, which involves the sur-
gical attachment of young to old organisms so they share a common
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vascular system, have revealed that the systemic environment has a
profound eﬀect on stem cell function and hippocampal neurogenesis. In
particular, speciﬁc youthful rejuvenating circulatory factors reverse
age-related declines in stem cell function and restore neurogenesis and
some associated hippocampal memory tasks, whereas the old milieu
contains inhibitory factors that impede stem cell function and neuro-
genesis when transferred to young animals (Villeda et al., 2014, 2011;
Villeda and Wyss-Coray, 2013).
Diet will impact on the composition of the systemic milieu and can
similarly modulate stem cell ageing, adult hippocampal neurogenesis,
and cognition (Murphy and Thuret, 2015). Therefore, modulation of
adult hippocampal neurogenesis by diet emerges as a possible me-
chanism by which nutrition can impact on cognitive ageing either via
the systemic milieu or via the gut-microbiota, as discussed earlier.
Given that both age and diet can alter stem cell function and neuro-
genesis, and that these alterations are facilitated by changes in the le-
vels of circulating factors, these inﬂuences should be investigated fur-
ther. Dietary interventions that potentially could promote healthy
ageing by enhancing stem cell function and neurogenesis are discussed
further below. There is now a need for dietary human interventions to
assess speciﬁc neurogenesis-dependent cognitive tasks such as pattern
separation.
3.2. Proteostasis and multi-dimensional controllers of ageing
In the early stages of brain ageing, neurons experience an imbalance
between protein production and protein clearance, which very likely
increases the risk of age-related protein accumulation pathology linked
to AD, Parkinson’s disease (PD), Huntington’s disease (HD), fronto-
temporal dementia (FTD), and other dementias (Bahr, 2009; Ross and
Poirier, 2004; Wang et al., 2018). AD is the most common multi-pro-
teinopathy, with phosphorylated tau and the Amyloid β42 (Aβ42)
peptide suspected as key pathogenic contributors (Glodzik-Sobanska
et al., 2009; Grundke-Iqbal et al., 1986). In 50–60% of AD cases, protein
accumulations also involve Tar-DNA binding protein-43 (TDP43), a
protein linked to FTDs and amyotrophic lateral sclerosis, as well as α-
synuclein, which accumulates in PD and related Lewy body diseases.
Tau and Aβ42 pathology has been found to propagate across the elderly
brain in cognitively normal women and men, and their deposition is
associated with distinctive patterns of grey matter loss (Sepulcre et al.,
2016). Moreover, the two proteins were found to be associated with
aberrant neural activity during memory encoding in cognitively healthy
older people, leading to declines in memory performance (Marks et al.,
2017). These studies broaden the concepts of cognitive ageing to il-
lustrate that controlling AD-type protein accumulation events during
ageing is important for the maintenance of mental performance in late-
life.
Strategies are needed to promote proteostasis in older age to control
the synthesis, folding, traﬃcking, and clearance of aggregation-prone
proteins in order to reduce occurrences of synaptic compromise and
dementia risk. Such strategic avenues will likely need to target multiple
pathogenic proteins to oﬀset dementia-related accumulation events,
often developing slowly for many years before memory problems arise.
Ubiquitously expressed chaperone proteins have been identiﬁed that
enable cells to cope with protein misfolding events, and the cellular
chaperones facilitate native folding and regulate the rates of protein
synthesis and clearance (Kalmar and Greensmith, 2017). Chaperone-
mediated autophagy degrades many types of proteins delivered to ly-
sosomes and may attenuate proteinopathy and ageing (Loos et al.,
2017). Drug targets for proteostasis continue to be identiﬁed to: 1)
induce chaperone levels and decrease the aggregation of diverse pro-
teins (Jimenez-Sanchez et al., 2015), 2) boost proteasomal protein
clearance activity to lower pathogenic tau levels, promote synaptic
maintenance, and improve cognitive performance (Farizatto et al.,
2017; Myeku et al., 2016), and 3) enhance enzymes of the autophagic-
lysosomal pathway to reduce protein accumulation stress and
associated synaptic pathology (Bendiske and Bahr, 2003; Butler et al.,
2011; Lee et al., 2004). The autophagy-lysosomal system plays a critical
role in protein clearance and neuronal homeostasis (Bahr et al., 2012;
Bendiske et al., 2002; Bendiske and Bahr, 2003; Mueller-Steiner et al.,
2006), aﬀording eﬃcient protein digestion and turnover and con-
tributing to cell health and possibly longevity (Folick et al., 2015).
Lysosomal enzymes such as cathepsin B represent therapeutic targets
for clearing age-related protein accumulations that lead to synaptic
pathology. An additional avenue to oﬀset age-related proteostatic stress
has been suggested to be through blocking the extralysosomal enzyme
calpain, leading to both induction of autophagy and positive protea-
somal regulation (see (Romine et al., 2017)).
The lysosomal protease, cathepsin B, responds to age-related protein
accumulation stress (Bahr, 2009; Bendiske and Bahr, 2003), perhaps as
a compensatory response that accounts for the gradual nature of disease
progression in most AD cases. Cathepsin B has been linked to tau
clearance (Farizatto et al., 2017), has been shown to degrade Aβ42
through carboxy-terminal truncation, and to correspondingly reduce Aβ
synaptic toxicity and neuropathology in transgenic mouse models and a
hippocampal slice model (Bahr et al., 2012; Butler et al., 2011; Mueller-
Steiner et al., 2006; Wang et al., 2012). Exercise, which is thought to
reduce the risk of AD, heart disease and other disorders, has recently
been shown to elevate cathepsin B in monkeys and humans, and the
elevated levels also correlate with improved hippocampal-dependent
memory (Moon et al., 2016). Taken together, this is consistent with
research suggesting that exercise may reduce age-related memory loss
and prevent or delay AD. In addition, enhancing lysosomal function has
been implicated as a strategy against α-synucleinopathy of PD and
Lewy body diseases (Lee et al., 2004). In relation to HD, enhancing
cathepsins B and D was found to protect against mutant Huntington
toxicity (Liang et al., 2011).
Further research to understand the importance of proteostasis is
recommended to identify positive modulators of the systems involved.
Positive cathepsin B modulators for reducing the risk of multi-protei-
nopathy may extend across synthetic and natural compounds. Eﬃcient
clearance of age-related protein accumulations may require enhance-
ment of both proteasomal and lysosomal systems, thus future eﬀorts are
needed to understand the distinct interactions between the two clear-
ance pathways in the brain (Farizatto et al., 2017) and to assess natural
and synthesized agents for distinct and dual modulatory eﬀects. Drugs
targeting only one type of pathogenic protein (Aβ42) have failed in
recent human trials for AD. However, a more hopeful outlook may be
provided by a compound that can target multiple proteins that accu-
mulate abnormally. While the usefulness of transgenic AD models for
screening potential therapeutics has been called into question in light of
failed clinical trials, this issue reiterates the importance of taking into
account the multi-proteinopathy aspect of the disease. Transgenic mice
may be missing dozens or even thousands of human proteins to prop-
erly replicate human AD, which is something probably vastly diﬀerent
than the disorders produced in mouse models. We may also never be
able to adequately model human brain ageing or dementia for precise
drug-discovery eﬀorts. For example, in a mouse’s short life, it is im-
possible to reproduce the everyday human stress that can span several
decades. Many human genetic factors and protein–protein interactions
may be involved in age-related cognitive decline. Targeting multiple
aspects of early proteinopathy provides a potential strategy to promote
cellular homeostasis and synaptic health for cognitive functions, per-
haps through combinations of pro-lysosomal and pro-proteasomal nu-
trition components. Promoting protein clearance pathways from middle
age may be needed to eﬀectively reduce the risk of age-related cogni-
tive impairment and extend the years with good mental performance
for optimal beneﬁt.
Ageing is a highly complex, pathophysiological process linking
metabolic alterations to the generation of accumulated cellular/tissue
damage, and has been shown to underpin a wide variety of disorders
associated with neurodegeneration (e.g. AD (Monacelli et al., 2017) and
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PD (Reeve et al., 2014), cardiovascular diseases (Ghebre et al., 2016),
and metabolic dysfunction (Brewer et al., 2016)). Highly complex
processes such as ageing may be regulated by a small group of systems
controlling multidimensional protein factors named ‘hubs’ (Balistreri
et al., 2016; Chadwick et al., 2012; Korwitz et al., 2016; Morris, 2013).
Hub proteins connect multiple signalling protein ‘nodes’ within a larger
network. This ‘higher-level’ of network connectivity between hubs
greatly enhances the speed and ﬁdelity of molecular coordination be-
tween functionally-related proteins/genes that control speciﬁc aspects
of (patho)physiology in a manner reminiscent of network bridging
factors in mathematical small-world network theory (Watts and
Strogatz, 1998). Identifying and therapeutically targeting these hubs,
before the onset of systemic age-related damage, may represent a novel
and highly eﬀective mechanism for treating age-related degeneration.
Research has identiﬁed the G protein-coupled receptor kinase inter-
acting protein 2 (GIT2) as a potential ‘hub’ molecule that controls the
ageing process by regulating the rate of damage accumulation, in the
form of oxidative stress and DNA damage, across the lifespan
(Chadwick et al., 2012, 2010; Lu et al., 2015; Martin et al., 2015;
Siddiqui et al., 2017). GIT2 acts as a molecular bridge between diverse
physiological processes that are interconnected in the ageing process.
Therefore, therapeutic control of this keystone factor likely represents
an important way forward for the treatment of age-dependent dis-
orders, such as AD and others related to neurodegeneration.
3.3. Oxidative stress, inﬂammation and mitochondria
The pharmacological manipulation of cellular-stress pathways is
emerging as a viable approach to treating certain neurologic diseases
such as AD, or psychiatric disorders such as schizophrenia (Calabrese
et al., 2016a; Calabrese et al., 2017b). For instance, increased oxidative
stress can damage mitochondrial proteins and has been implicated as a
contributory factor to AD pathogenesis. To adapt to environmental
changes and survive diﬀerent types of injuries, brain cells have evolved
networks of responses that detect and control diverse forms of stress.
Consistent with this notion, integrated survival responses exist in the
brain, which are under control of redox-dependent genes, called vita-
genes, including heat shock proteins (Hsps), sirtuins, thioredoxin, and
lipoxin A4 (LXA4) (Calabrese et al., 2011). Vitagenes network is com-
posed, besides those mentioned above, by genes, such as Nrf2-depen-
dent enzymes heme oxygenase and γ-glutamyl cysteine ligase, which
sense redox perturbations, including oxidative damage, and actively
operate in promoting cell survival under physiopathological conditions
(Calabrese et al., 2011). LXA4 as an endogenously produced eicosanoid,
which blocks the generations of pro-inﬂammatory cytokines and toxic
compounds including reactive oxygen species (ROS), promotes resolu-
tion of inﬂammation, and acts as an endogenous “breaking signal” in
the inﬂammatory process. Additionally, recent evidence linking the
restoration of redox homeostasis by nutritional mushrooms (e.g. Cor-
iolus versicolor, Hericium erinaceus), suggests potential neuroprotective
strategies in brain ageing and neurodegenerative disease aimed at in-
ducing the vitagene defence system mechanism (Trovato et al.,
2016a,b).
Recent studies have demonstrated that the inﬂammasome mod-
ulates neuro-inﬂammatory processes at the initial stage, followed by a
secondary cascade of events including oxidative stress (Freeman and
Ting, 2016). Inﬂammasomes are multiprotein complexes assembled in
response to infection, cell damage, or environmental stress. The AIM2
inﬂammasome is activated by cytosolic DNA and in addition, it has
recently been demonstrated that mitochondria represent major sources
of Damage-Associated Molecular patterns (DAMPs) capable of trig-
gering neuro-inﬂammatory responses, with resulting apoptosis and
pyroptosis (highly inﬂammatory form of programmed cell death). In-
appropriate recognition of cytosolic DNA by AIM2 contributes to the
development of a number of autoimmune and inﬂammatory diseases
and neurodegenerative disorders. The pharmacological modulation of
exogenous/endogenous stress, as discussed above, may be framed
within the context of hormesis, a dose response phenomenon, char-
acterized by low-dose stimulation and high-dose inhibition. Numerous
pharmacological agents and chemical stressors, when acting at low
doses, are able to upregulate adaptive responses that protect against
subsequent noxious stimuli in a broad range of cellular conditions due
to normal and pathological ageing processes, as well as damage induced
by exogenous agents, such as ionizing radiation and toxic chemicals
(Calabrese et al., 2017a; Calabrese et al., 2010; Calabrese et al., 2016b;
Pennisi et al., 2017). These hormetic-dose responses are independent of
the biological model, cell type, endpoint, and chemical class/physical
agents and mechanisms. They are therefore highly generalizable and a
fundamental evolutionary strategy. In addition, the phenomenon of
pre-conditioning and post-conditioning have also been shown to con-
form to the quantitative features of the hormetic dose response and are
now considered to be manifestations of hormesis (Calabrese et al.,
2017a).
3.4. Non-coding RNAs and miRNAs
Coding transcripts responsible for protein expression make up less
than three per cent of the human genome. Recently, it has been found
that around 80 per cent of the human genome is transcribed into non-
coding RNAs, with a substantial amount of these being functionally
active RNAs. Non-coding RNAs are divided into 2 groups called small
non-coding RNAs (e.g. microRNAs) and long non-coding RNAs (e.g.
IncRNAs) (An integrated encyclopedia of DNA elements in the human
genome, 2012; Uchida and Dimmeler, 2015). Non-coding RNAs play an
important role in regulating a large number of cellular functions and
physiological processes. In the brain, they have been shown to play a
role in the regulation of diﬀerent brain functions, such as neural stem
cell maintenance, neurogenesis and gliogenesis, brain patterning, sy-
naptic and stress responses, and neural plasticity (Huang et al., 2017).
Studies on ageing processes, as well as the characterization of various
neurodegenerative diseases using diﬀerent genetic models (e.g. yeast,
ﬂy, mouse, and human systems), have demonstrated the role of these
non-coding RNAs on brain function/dysfunction (Szafranski et al.,
2015), implicating a variety of RNA-regulatory processes. For example,
R-loop formation and RNA accumulation represent mechanisms in
brain ageing and neurodegeneration. Long non-coding RNAs have been
suggested to regulate depression (Huang et al., 2017). MicroRNAs
(miRNAs) are an abundant class of short non-coding RNAs that regulate
a variety of cellular processes through the post-transcriptional regula-
tion of gene expression (He and Hannon, 2004). miRNAs have also been
shown to regulate processes associated with brain ageing, declining
brain function, and neurodegenerative diseases (Karnati et al., 2015).
For instance, miRNAs have been identiﬁed as critical players in fun-
damental brain development processes, such as neuronal diﬀerentia-
tion, neuronal longevity, and survival. miRNA dysfunction may trigger
overt neuronal degeneration and neurodegenerative disease-associated
pathways (Szafranski et al., 2015). For example, the level of two pro-
teins, amyloid precursor protein (APP) and membrane-bound proteases
β-site APP-cleaving enzyme 1 (BACE1), which contribute to the for-
mation of amyloid plaques in AD, are controlled by miRNAs (Salta and
De Strooper, 2012). AD is characterized by the accumulation of amyloid
plaques in the brain, consisting of an aggregated form of amyloid β-
peptide derived from sequential amyloidogenic processing of the APP
by BACE1 and γ-secretase (Toh and Gleeson, 2016). In the adult mouse
brain, deletion of Dicer (an enzyme responsible for the ﬁnal maturation
of precursor miRNA (Shukla et al., 2011)), resulted in neurodegenera-
tion and tau pathology (Hébert et al., 2010). In PD, reduced expression
of miR-34b and miR-34c has been identiﬁed in the aﬀected brain areas
including the frontal cortex, cerebellum, substantia nigra, and amyg-
dala. The reduction of these miRNA molecules is thought to cause mi-
tochondrial dysfunction and oxidative stress, as well as the lower ex-
pression of DJ1 and Parkin proteins related to both familial and
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idiopathic cases (Minones-Moyano et al., 2011). miR-9miR-9* expres-
sion is reduced with disease progression of HD (Packer et al., 2008),
leading to an increase in REST protein, and consequently suppression of
neuronal gene expression that contributes to neuropathology (Junn and
Mouradian, 2012). miR-132 was shown to maintain neurite growth by
inhibiting its mRNA target, p250GAP (Vo et al., 2005). In mouse models
of HD and post-mortem tissue of HD patients, miR-132 was found to be
signiﬁcantly lower, providing support for the abnormal regulation of
neurite growth (Dantzer et al., 2008). Furthermore, miRNAs dysfunc-
tion has been implicated downstream of some key RNA-binding pro-
teins such as TDP43. As mentioned earlier, TDP43 is linked to dementia
and amyotrophic lateral sclerosis. TDP43 may additionally act as a
regulator of miRNA biogenesis and function, and this appears as an
important pathogenic mechanism in neurodegenerative diseases
(Szafranski et al., 2015).
4. Nutritional strategies to modulate mechanisms and
vulnerabilities to poor cognitive ageing
The rate and severity of cognitive decline during normal ageing can
be attenuated by a wide variety of factors, such as improved nutrition
and appropriate dietary supplementation (Swaminathan and Jicha,
2014). Some of those nutrients or dietary interventions involved are
detailed below.
4.1. n-3 PUFAs
Prospective observational studies indicate that Mediterranean-like
diets (i.e. diets high in ﬁsh, olive oil, nuts and vegetables) may postpone
the onset of dementia (Martínez-Lapiscina et al., 2013; Scarmeas et al.,
2006; Soﬁ et al., 2008). Omega-3 polyunsaturated fatty acids (n-3
PUFA) may have primary preventive eﬀects on dementia, although
mainly positive observational studies are so far not conﬁrmed by in-
tervention studies (Mazereeuw et al., 2012; Morris et al., 2005; van de
Rest et al., 2009; Zhang et al., 2016). n-3 PUFA may have secondary
preventive eﬀects when given to older subjects with early memory
disturbances (Freund-Levi et al., 2006). Nutrition most likely cannot
aﬀect AD or other dementia types when the conditions are already es-
tablished (Burckhardt et al., 2016). Thus, healthy nutrition like Medi-
terranean-like dietary patterns or n-3 PUFA may be able to prevent or
postpone disease processes, but may not be able to reverse the disease
process or to dissolve the pathogenic deposited substances in the brain.
A n-3 PUFA enriched supplement or oral nutrition support with ba-
lanced content of macronutrients for energy as well as of micronutrients
like vitamins, minerals, and trace elements may positively aﬀect weight
and appetite in patients with mild to moderate AD and other cognitive
diseases, and will maintain nutritional status and contribute to better
general functionality (Allen et al., 2013; Irving et al., 2009). In animal
models of AD, long-term fatty acid supplementation decreases the n-6/
n-3 ratio and improves cognitive function, suggesting that the duration
of supplementation may be a reason why no eﬀects of n-3 PUFA sup-
plementation could be observed in patients with moderate or advanced
AD (Hooijmans et al., 2012). Perspectives for future human studies are
thus to clearly deﬁne the population that will be subjected to the in-
tervention trial and to include enough participants, as enabling a long
enough duration of the intervention (Sydenham et al., 2012).
Experimental studies provide insights into feasible mechanisms for
the potential beneﬁcial n-3 PUFA eﬀects on cognitive functions
(Chakraborty et al., 2017; Hooijmans et al., 2012). Docosahexaenoic
acid (DHA), representing 10–20% of the brain cells lipids, is known to
play multi-functional roles in brain health and diseases. DHA and
PUFAs regulate several processes within the brain via their mediators,
such as neurotransmission, cell survival, and neuroinﬂammation, and
thereby mood and cognition (Bazinet and Laye, 2014; Sun et al., 2017).
In animal models, decreased n-3 PUFA alter emotional behaviour and
memory, and an inverse relation between ﬁsh-derived n-3 PUFA (DHA
and eicosapentaenoic acid (EPA)) consumption and prevalence of
cognitive decline has been found in humans, with decreased levels of n-
3 PUFA in the blood and the brain of aged patients with cognitive
impairment (Bazinet and Laye, 2014). Chronic inﬂammation in the
brain together with microglia activation can lead to neuronal damage.
Recent evidence indicates that n-3 PUFA and ﬂavonoids play a role in
preventing neuroinﬂammation and modulating age-related memory
decline (Vauzour et al., 2015). They act as potent anti-inﬂammatory
bioactives, resolving inﬂammation through several pathways, i.e. sup-
pressing the activation of microglia through the down-regulation of
cytokine expression and the modulation of signalling pathways in-
volved in the resolution of inﬂammation (Vauzour et al., 2015). n-3
PUFA also harvest protective eﬀects indirectly, through the synthesis of
bioactive mediators with pro-resolutive activities such as resolvins
(Vauzour et al., 2015). Resolvins (D1 and E1) derived from DHA and
EPA are promising therapeutic compounds to target brain inﬂammation
(Rey et al., 2016).
4.2. Amino acids
Tyrosine is a conditionally-essential, large, neutral amino-acid,
which is the precursor of the catecholamines (e.g. dopamine and nor-
adrenaline). Tyrosine is naturally present in protein-rich foods, such as
meat, ﬁsh, dairy products, but also in nuts, seeds, and beans. Oral ad-
ministration of tyrosine leads to increased catecholamine synthesis,
especially dopamine (Growdon and Melamed, 1980; McTavish et al.,
1999; Scally et al., 1977). Dopamine is important for cognitive control
functions (for a review, see (Cools and D’Esposito, 2011; van
Schouwenburg et al., 2010), including working memory and response
inhibition. Tyrosine administration increased cognitive control func-
tions in cognitively healthy, young adults, both under stress (Deijen
et al., 1999; Deijen and Orlebeke, 1994; Mahoney et al., 2007; Shurtleﬀ
et al., 1994; Thomas et al., 1999), which accelerates catecholamine
metabolism (Bliss et al., 1968) and in normal circumstances (Colzato
et al., 2014, 2013; Steenbergen et al., 2015). Ageing is accompanied by
a decline in dopamine signalling (Bäckman et al., 2011, 2006) and
associated impairments in cognitive control, such as working memory
(Gazzaley et al., 2005; Li and Rieckmann, 2014; Turner and Spreng,
2012) and response inhibition (Bedard et al., 2002; Bloemendaal et al.,
2016; Van de Laar et al., 2012). Under which circumstances tyrosine
would increase cognitive control functions in cognitively healthy older
adults is still to be established. However, it seems likely that tyrosine
administration would be especially beneﬁcial in the case of neuroin-
ﬂammation. Tyrosine is the precursor of L-Dopa in the dopamine
synthesis pathway. The synthesis of L-Dopa from tyrosine depends on
tyrosine hydroxylase and its cofactor tetrahydrobiopterin (BH4). Re-
active Oxygen Species (ROS) that are generated downstream of in-
ﬂammatory activity can inactivate BH4 (Neurauter et al., 2008),
thereby aﬀecting dopamine synthesis. Studies in humans and non-
human primates have indeed shown inﬂammation-associated reduc-
tions in dopamine signalling (Felger and Treadway, 2017). Adminis-
tration of the dopamine precursor L-Dopa reversed the detrimental ef-
fect of pro-inﬂammatory cytokine IFN-α on striatal dopamine release in
non-human primates (Felger et al., 2015). Increasing L-Dopa’s pre-
cursor tyrosine, by dietary supplementation, might similarly be ad-
vantageous in reducing the negative eﬀects of inﬂammation-associated
inactivation of BH4 on dopamine synthesis eﬃciency.
Large neutral amino-acid precursors of neurotransmitters, such as
tyrosine and its precursor phenylalanine can also be synthesized by gut
microbiota (Clayton, 2012; Gertsman et al., 2015). These microbial-
produced precursors might be absorbed through the intestinal epithe-
lium, enter the portal circulation, cross the blood-brain barrier, and
inﬂuence host catecholamine synthesis (Lyte, 2013). Indeed, a recent
study in young adults demonstrated that predicted microbial synthesis
of phenylalanine was associated with altered neural reward processing
in the ventral striatum (typically dependent on dopamine processing)
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(Aarts et al., 2017). Interactions between dietary catecholamine pre-
cursors and microbial neurotransmitter precursor synthesis should be
taken into account when considering the beneﬁcial eﬀects of dietary
phenylalanine and tyrosine in aging.
The essential, large, neutral amino-acid, tryptophan, is the pre-
cursor of serotonin (and melatonin). Tryptophan is found in nearly all
protein-containing foods. Dietary intake of tryptophan inﬂuences ser-
otonin synthesis and release in the brain (Fernstrom, 1983). Serotonin
is involved in a variety of neurocognitive functions, including sensor-
imotor function, learning, and memory (Muller and Jacobs, 2009).
Tryptophan administration in young adults has been shown to improve
memory (for a review, see van de Rest et al., 2013). Similar to tyrosine,
studies of tryptophan administration in cognitively healthy older adults
are mostly lacking, even though serotonin signalling also declines with
ageing (McEntee and Crook, 1991). Interestingly, the above-mentioned
mechanism of ROS-induced inactivation of BH4 is relevant for ser-
otonin synthesis as well, as tryptophan hydroxylase,needed for con-
version of tryptophan into 5-Hydroxy-tryptophan (5-HTP), which in
turn is converted into serotonin (5-Hydroxy-tryptamine, 5-HT), is de-
pendent on cofactor BH4 also. However, there is another important
inﬂammation-related mechanism associated with tryptophan. Speciﬁ-
cally, pro-inﬂammatory cytokines, such as IFN-γ, IL-1β, and TNF-α
catalyse the conversion of tryptophan into kynurenine at the expense of
serotonin production, by inducing the expression of indoleamine 2,3-
dioxygenase (IDO) (O’Connor et al., 2009a, 2009b). Subsequently, ky-
nurenine is metabolized by microglia into, amongst others, quinolinic
acid, a neurotoxic that generates ROS. Indeed, the kynurenine/trypto-
phan ratio in blood is increased in AD and related to decreased cogni-
tive performance (Widner et al., 2000). Kynurenine can also be con-
verted to kynurenine acid with neuroprotective properties. However, in
rats, tryptophan administration increased brain levels of the neurotoxic
quinolinic acid to a much greater extent than levels of the neuropro-
tetive kynurenine acid and even that of serotonin (Freese et al., 1990).
Thus, given the potential conversion to kynurenine and quinolinic acid,
dietary supplementation of tryptophan should be done with caution. On
the other hand, commensal bacteria can catabolize dietary tryptophan
to indole, indole-3-aldehyde, and indole-3-propionate, with potential
anti-inﬂammatory eﬀects (for a review, see (Zhang and Davies, 2016)).
However, given that the gut microbiome is aﬀected by aging, as dis-
cussed above, the beneﬁcial eﬀects of tryptophan consumption in this
regard still needs to be elucidated.
4.3. Polyphenols
Polyphenols are micro-constituents of plant-based foods, which are
widely distributed in the human diet. The main dietary sources of
polyphenol intake are fruits and fruit-derived products (Pérez-Jiménez
et al., 2010), which is a main constituent of the Mediterranean-style
diet. Adherence to a Mediterranean diet is associated with slower
cognitive decline, and reduced incidence of dementia and AD (Vauzour
et al., 2017). Epidemiological studies suggest an inverse relationship
between the intake of diﬀerent classes of polyphenols and the risk of
diﬀerent age-related diseases, such as cardiovascular diseases, cancer,
or metabolic disorders (Vauzour et al., 2010). The potential of these
compounds to prevent neurodegenerative disorders is also documented
in several animal studies. For example, it has been shown that diets
supplemented with blueberry (a fruit rich in anthocyanins) improve the
performance of aged animals in spatial working memory tasks
(Williams et al., 2008). Several clinical studies have also demonstrated
potential beneﬁcial eﬀects of polyphenol-rich fruit on brain function
(Khalid et al., 2017; Miller et al., 2017; Valls-Pedret et al., 2012). One
study revealed that consumption of ﬂavanone-rich orange juice is
beneﬁcial for cognitive function in cognitively healthy older adults with
no signiﬁcant eﬀects on mood or blood pressure (Kean et al., 2015),
while consumption of cocoa ﬂavanols beneﬁcially aﬀects cognitive
performance and mood during highly eﬀortful cognitive processing
(Scholey et al., 2010). This potentially beneﬁcial eﬀect of polyphenol
rich-food on brain function may be linked to increased blood ﬂow in the
brain (Lamport et al., 2015). Nutritional intervention with high-ﬂa-
vanol drinks for three months has been shown to signiﬁcantly increase
cerebral blood volume in the dentate gyrus area of the hippocampus
and signiﬁcantly enhance performance (reaction time) on a pattern
separation task (Brickman et al., 2014). Pattern separation tests, which
test the ability to distinguish between previously presented pictures and
very similar ones, can be directly related to activity in the dentate
gyrus, an area where neurogenesis occurs (Bakker et al., 2008).
Therefore, age-related decline in the ability to discriminate closely si-
milar pictures reﬂects reduced activity in the dentate gyrus (Toner
et al., 2009; Wesnes, 2010). Importantly, deﬁcits in this task have been
linked to the genotype associated with susceptibility to AD as well as
cerebrospinal levels of Aβ42 (Wesnes et al., 2014).
Even though data exists revealing the positive eﬀect of polyphenols
on brain and vascular function, the mechanisms of action underlying
their beneﬁcial eﬀects appear to be complex and are not fully under-
stood yet (Field et al., 2011; Scholey et al., 2010; Vauzour et al., 2017).
A large number of in vitro studies exist showing the capacity of poly-
phenols to modulate not only the expression of genes, but also ex-
pression of miRNA and proteins, and induce epigenetic modiﬁcations
(Claude et al., 2014; Krga et al., 2016; Mandel et al., 2008; Schroeter
et al., 2007, 2001; Vauzour et al., 2007). Most of these studies have
been performed using native forms of polyphenols (forms found in
fruits) at high concentrations. However, the bioavailability of ingested
polyphenols is generally low and most often the absorbed forms are not
the native compounds (Bohn et al., 2015). The forms present in the
circulation that can reach target tissues result from extensive metabo-
lism involving both enzymatic activities of the gut microbiota (Tomas-
Barberan et al., 2016; Williamson and Cliﬀord, 2017) and endogenous
conjugative enzymes (Espin et al., 2017). Plasma metabolites of poly-
phenols are mainly either conjugated derivatives, in glucuronidated-,
sulphated-, and methylated-forms, or metabolites of microbial origins
found at concentrations in nano to few microM ranges. Taken together,
knowledge of the molecular and cellular mechanisms of action is in-
complete. Further studies are needed to enhance our knowledge of the
mechanisms linking these bioactives with health beneﬁts.
4.4. Multi-nutrient interventions
Single nutrient interventions have generally shown no cognitive
beneﬁt in mild cognitive impairment (MCI) and AD (Aisen et al., 2008;
Dysken et al., 2014; Freund-Levi et al., 2006; Galasko et al., 2012;
McMahon et al., 2006; Petersen et al., 2005; Quinn et al., 2010). It is
likely that the potency of single nutrients is insuﬃcient to achieve a
clinically relevant beneﬁt. A hypothesis-driven speciﬁc nutrient com-
bination (called Fortasyn Connect) of uridine, docosahexaenoic acid,
eicosapentaenoic acid, choline, phospholipids, folic acid, vitamins B12,
B6, C, E, and selenium has been designed to ameliorate synapse loss,
synaptic dysfunction, and other pathological pathways aﬀected in AD
by addressing distinct nutritional needs believed to be present in these
patients (Van Wijk et al., 2014). This speciﬁc nutrient combination is
based on the notion that cognitive decline in MCI and AD is a result of
loss of synapses (de Wilde et al., 2016). Formation of synapses is rate-
limited by speciﬁc nutrients that are the precursors for the formation of
neuronal membranes and act by enhancing the substrate-saturation of
the enzymes that catalyze the rate-limiting steps of membrane phos-
pholipid synthesis through the Kennedy Pathway (Wurtman et al.,
2009). Beneﬁcial and synergistic eﬀects of the speciﬁc nutrient com-
bination of precursors and cofactors of neuronal membrane formation
have been demonstrated in several animal models by various groups
and on several biological phenomena that are indicative of increased
synapse formation and function and other pathological processes that
are characteristic of AD, and published in over 30 peer-reviewed pub-
lications (Cansev et al., 2015; Janickova et al., 2015; Van Wijk et al.,
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2014; Wiesmann et al., 2016; Wurtman et al., 2009). These results
suggest that people with AD pathology may beneﬁt from increased
intake of these nutrients. Importantly, meta-analyses show that the le-
vels of these nutrients in circulation and in the brain are lower in AD
than in non-AD controls (Lopes Da Silva et al., 2014). Collectively, these
insights indicate that the nutritional need for these nutrients is higher in
AD and led to the development of Souvenaid, a medical food for early
AD comprising this speciﬁc nutrient combination (Van Wijk et al.,
2014). The clinical eﬃcacy of Souvenaid was tested in a clinical trial
program, with trials in AD patients at various stages of AD, and on
clinical outcomes as well as neuroimaging measures. Studies in drug-
naïve mild AD showed that the intervention increased magnetic re-
sonance spectroscopy measures of brain neuronal membrane synthesis
(Rijpma et al., 2017) and electroencephalography (EEG) measures of
functional connectivity and functional brain network organisation (De
Waal et al., 2014; Scheltens et al., 2012); while in prodromal AD, a 2-
year Randomised Control Trial (RCT) showed reduced hippocampal
atrophy (Soininen et al., 2017). Studies in drug-naïve mild AD showed a
signiﬁcant beneﬁt on memory performance (Rikkert et al., 2015;
Scheltens et al., 2012, 2010), the primary endpoint in these RCTs and
the most pronounced clinical symptom of early AD. More recently, an
independent EU funded 2-year RCT in prodromal AD reported favour-
able eﬀects on memory and a clinical relevant combined measure of
cognition and function (CDR-SB) (Soininen et al., 2017). In conclusion,
mechanistic studies on this speciﬁc nutrient combination together with
the Souvenaid clinical trials in AD show consistent eﬀects on brain
function, metabolism, structure, and measures of cognition and func-
tion that corroborate the working mechanism of the speciﬁc interven-
tion (De Waal et al., 2014; Hartmann et al., 2014; Rijpma et al., 2017;
Scheltens et al., 2012, 2010; Soininen et al., 2017). In addition, these
studies together support the notion that clinical relevant beneﬁt on
brain function in ageing can be achieved by a hypothesis-driven nu-
trient combination that ampliﬁes the potency of single compounds (von
Arnim et al., 2010).
5. Application and impact
5.1. Multi-domain interventions
Epidemiological studies demonstrate that links exist between nu-
trition, physical activity, and cognitive and social stimulation that help
to improve brain health. As prevention has been advocated as an ef-
fective way to reduce the burden of AD (Norton et al., 2014), multi-
domain interventions seem therefore appropriate to target the multiple
factors involved in cognition and ageing. The Finnish Geriatric Inter-
vention Study to Prevent Cognitive Impairment and Disability (FINGER,
NCT01041989) was a 2-year multicentre randomized controlled trial
with 1260 participants aged 60–77 years recruited from previous po-
pulation-based survey cohorts. The multi-domain intervention included
four components: nutritional guidance, physical exercise, cognitive
training and social activities, and management of vascular/metabolic
risk factors. The control group received regular health advice. The
primary outcome after two years was change in cognition (neu-
ropsychological test battery, NTB z-score). FINGER is the ﬁrst ‘proof-of-
concept’ trial showing that a multi-domain lifestyle intervention had
signiﬁcant beneﬁcial eﬀects on cognition in an at-risk older general
population (Ngandu et al., 2015). Signiﬁcant intervention eﬀects were
also found for several secondary outcomes (e.g. dietary habits, body
mass index, physical activity, quality of life, and disability). Key de-
terminants of intervention success were: the combination of group ac-
tivities with individualized, concrete counselling (facilitating both
personal and within-group motivation and support for healthy lifestyle
changes), knowledgeable staﬀ, providing positive feedback, and inclu-
sion of community support. FINGER showed that a multi-domain life-
style intervention in at-risk older individuals is feasible and safe.
Compliance was high, and participants’ experiences were very positive.
Other European multi-domain interventions oﬀer some additional
insights. The Prevention of Dementia by Intensive Vascular care
(preDIVA) trial tested a 6-year multi-domain vascular intervention in-
cluding dietary advice in 3526 older individuals (age 70–78 years) from
general practices in the Netherlands (Moll van Charante et al., 2016).
The control group received usual care. The intervention did not result in
a reduced incidence of all-cause dementia in this unselected sample of
older people in a general practice setting with high standards of usual
care. However, some beneﬁts on dementia incidence were noted in at-
risk subgroups (e.g. participants with untreated hypertension at base-
line who adhered to the intervention).
The Multi-domain Alzheimer Preventive Trial (MAPT) study was
designed to test whether a combination of nutritional counselling,
physical exercise, and cognitive stimulation, together with n-3 PUFA
supplementation, is eﬀective in slowing cognitive decline in frail older
adults at risk of cognitive decline (Andrieu et al., 2017; Vellas et al.,
2014). The MAPT trial is the ﬁrst largest and longest multi-domain
preventive trial relevant to cognitive decline in older adults with sub-
jective memory complaints, and is easily implementable in the general
population. This multi-domain intervention brings some hope regarding
long-term eﬀects of a multi-factorial approach to prevent development
of impaired cognition (Andrieu et al., 2017; Vellas et al., 2014).
Nevertheless, additional trials are needed to conﬁrm these observa-
tions.
Findings from the FINGER, preDIVA and MAPT trials thus suggest
that preventive interventions may need to be adequately targeted to at-
risk populations in order to be most eﬀective. Interventions may also
need to be suﬃciently intensive for beneﬁts to become apparent. In
conclusion, the various research innovations described above will en-
able trials to be conducted on scales which were not previously pos-
sible, with numerous treatment arms to allow optimal combinations of
various interventions to be established for multiple groups of in-
dividuals having shared genotypes as well as phenotypes. This ﬁeld has
now entered the ‘big data’ era, which will enable research questions to
be addressed that previously were not feasible even to propose.
5.2. Relevance for public health and regulatory implications
The increased ageing population and rise in cognitive decline ex-
pectedly impacts public health. Future outcomes relevant for public
health include development of health claims related to improvement of
cognitive function. For instance a claim on ‘DHA and improvement of
memory function’ was recently approved by EFSA (EFSA Panel on
Dietetic Products, 2016). A claim for ‘cognitive function’ requires evi-
dence for an eﬀect involving several speciﬁc domains and outcomes,
emphasising the multi-factorial aspect of the ageing process. Further-
more, some EU initiatives highlight the importance of health and nu-
trition in the centre of attention. Besides the huge socio-economic im-
pact of healthy and most notably, pathological ageing, the increasing
relevance of global public health highlights the growing interest in
understanding cognitive function and healthy ageing, with nutrition as
spearhead.
In respect of pathological ageing, research interest and regulatory
requirements are moving towards studies in cognitively healthy in-
dividuals, either carrying speciﬁc biomarkers of pathological ageing or
in those ageing in the absence of disease. This supports the hypothesis
that factors such as diet will help maintain healthy ageing and is crucial
to help prevent or delay the onset of neurodegenerative disorders
(Harvey et al., 2017; Kozauer and Katz, 2013; Roses et al., 2013; Small
and Vorgan, 2012; Sperling et al., 2011; Whitehouse, 2014).
6. Conclusion and future directions
The ILSI Europe workshop ‘Nutrition for the ageing brain: func-
tional aspects and strategies’ and the present paper highlight the value
of combining studies of cognitive ageing with well-designed studies
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investigating how dietary interventions can be a strategy to target the
mechanisms of ageing. However, to advance, future research in this
ﬁeld may need to adopt a longitudinal approach to ensure the eﬀect of
early-life stress is adequately measured. Interventions may also need to
be imposed prior to the onset of pathological cognitive ageing.
Researchers will need to consider factors, such as epigenetic changes or
gut microbiome diversity in the ageing process. Innovation in research
and the development of new technologies will enable trials to be con-
ducted on scales which have not previously been possible, with nu-
merous treatment arms to allow optimal combinations of various in-
terventions to be established for multiple groups of individuals that
have shared genotypes as well as phenotypes.
Longitudinal monitoring of cognition across the lifespan is essential
for eﬀective dementia prevention. Integrative approaches are required
that are sensitive to the synergistic action of various risk and protective
factors and their possible common pathways. One major question for
the ﬁeld is whether these various lifestyle choices all compete for a
limited opportunity to enhance cognitive function, or whether the ef-
fects could be additive or even synergistic. Individual variations in risk
proﬁles for dementia must also be taken into account, as diﬀerent
lifestyle choices may have diﬀerent contributions to the overall risk in
diﬀerent people. Cognitive function is a broad topic and it would be
advantageous if the research community could agree on which cogni-
tive tests to use as outcome measures. As Matthews et al. (2013) argue,
whether prevalence rates will continue to rise, ‘will probably depend on
whether further improvements in primary prevention and eﬀective
health care for disorders that increase the risk of dementia can be
achieved, including addressing inequalities’ (Matthews et al., 2013).
The aetiologies of dementia and age-related cognitive decline are
multi-factorial, therefore, it is likely that multi-dimensional interven-
tions will be required to eﬀectively delay dementia onset. Large-scale
dementia prevention studies are essential to address the current gaps in
knowledge and accelerate advances through multifactorial approaches.
In addition, it is also crucial to widen the scope of our current concept
of potential patho-mechanisms that contribute to cognitive decline,
both at the level of the central nervous system and also peripheral
tissues. A multifaceted approach to identify new viable strategies is
vital for the creation of new and eﬀective therapeutics. International
collaborations within extensive networks, including partners from both
academia and industry, are already starting to be established. Some key
issues for future dementia prevention research are: the harmonisation
and optimisation of methodologies for multinational and multi-domain
prevention trials across the entire spectrum of cognitive impairment
and AD, international sharing of expertise and data, rethinking pre-
vention trials (e.g. adaptive designs, inclusion of e-health components,
combining non-pharmacological and pharmacological approaches to
prevention), and learning from experiences with prevention research in
other ﬁelds (Geerts et al., 2016).
The longitudinal epigenetic characterisation of population sub-
groups, which follow a speciﬁc diet for many years, may also yield
useful information on transient versus persistent epigenetic changes/
epigenetic ageing in the presence/absence of speciﬁc diets (e.g. vege-
tarian, Mediterranean, vegan, etc.) and information related to other
lifestyle factors (e.g. regularity and intensity of exercise). Such studies
should evaluate the separate and interactive eﬀects of factors, such as
nutrition and physical exercise on epigenetic modiﬁcation. Suitable
approaches might include the development of mobile phone applica-
tions to measure health and diet/physical exercise. Integrated data
analysis pipelines should be developed to explore epigenetic bio-
markers in saliva, blood, cerebrospinal ﬂuid, and cognitive imaging
data.
The ways that changes in the levels of circulating factors (e.g.
Insulin Growth Factor 2 (IGF2) or the Growth and Diﬀerentiation
Factor 11(GDF11)) facilitate age- and diet-induced eﬀects on stem cell
function, neurogenesis, and brain function need to be identiﬁed and
investigated further. Dietary interventions that tip the balance of
factors towards a rejuvenating milieu are potentially eﬀective means to
promote healthy cognitive ageing by enhancing stem cell function and
neurogenesis (Murphy and Thuret, 2015). There is currently a real need
for dietary human interventions coupled with in vitro assays involving
immortalized human stem-cell lines, and neurogenesis-dependent cog-
nitive tasks such as pattern separation, which targets the dentate gyrus
(Bakker et al., 2008). Although the dentate gyrus is suggested to reg-
ulate neurogenesis, the only information in humans supporting this is
based upon blood perfusion using fMRI (Brickman et al., 2014). There
are currently no real ways of measuring neurogenesis in human brain
tissue and most of the information gathered to date is derived from
animal studies.
In the case of polyphenols, it is important to perform clinical trials
using well-deﬁned controls to identify a proper role of compounds
(such as ﬂavanols) on brain function. Further in vitro studies will be
necessary, together with pre-clinical studies, to identify as precisely as
possible the cellular and molecular mechanisms of action of poly-
phenols. Future studies should take into account the multiple targets
and multiple modes of action of polyphenols. These studies should si-
multaneously investigate the impact of polyphenols on the of expres-
sion of genes, non-coding RNAs, proteins, and other regulators of cell
function, such as cell signalling pathways or epigenetic modiﬁcations to
identify molecular mechanism(s) of action. For in vitro studies, circu-
lating forms of polyphenol metabolites at physiologically relevant
concentrations should be used.
Future studies should also assess the peripheral and central me-
chanisms underlying potential age-related diﬀerences in tyrosine or
tryptophan eﬀects on cognition in placebo-controlled designs, with
both young and older adults. When assessing the eﬀects of age, long-
itudinal designs are preferred, as cross-sectional designs cannot easily
control for between-subject diﬀerences other than age. Amino-acid
administration studies in older adults should also use longer supple-
mentation designs, as eﬀects of auto-regulation of monoamine synthesis
might diﬀer for acute administration with high doses versus supple-
mentation with continuous lower doses.
In the case of fatty acids, it is important to take into account the
regular baseline ﬁsh or n-3 PUFA intake, or baseline serum concentra-
tions of DHA as well as EPA. Recent studies demonstrated that higher
levels of DHA/EPA may help protect against the development of de-
mentia (Ammann et al., 2017). If the intake or the serum levels are
already suﬃcient, further beneﬁcial eﬀects of fatty acid supplementa-
tion is not to be expected. This would be like performing a study on
blood pressure medication without knowing the baseline blood pressure
and also providing normotensive subjects with the test medication!
Most of the clinical trials recruit patients with high DHA/EPA baseline
values and it is therefore recommended to include only subjects with
low intake of ﬁsh or low levels of DHA/EPA in the intervention studies,
even though a threshold needs to be deﬁned.
Priorities for future studies are to clearly deﬁne the population that
will participate in the intervention trial. Proof of concept studies are
needed to design proper RCTs with suﬃcient power. Also, dose aspect is
also a disadvantage, as many of the animal studies investigating me-
chanisms are supra-physiological and not achievable in humans
without risk of toxicity, e.g. green tea catechins producing hepato-
toxicity at 500mg/day (Isomura et al., 2016).
Research suggests it is possible to amplify the potency of nutrient
intervention by combining nutrients that work synergistically to ensure
the neuroprotective potential of nutrition is fully leveraged. The
blending of nutrients should be hypothesis driven and based on the
speciﬁc contribution of each nutrient to the targeted biological pathway
(s) that underlie cognitive eﬀects. Therefore, future research should aim
to: 1) increase understanding of the role of speciﬁc nutrients on bio-
logical pathways that are relevant to cognitive ageing, 2) design and
validate nutrient combinations to target mechanisms of cognitive
ageing, 3) validate multi-nutrient combinations in well-designed clin-
ical studies, and 4) transfer knowledge of the role of nutrition for
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cognitive health to recommendations for public health.
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